AAAAAA

   
Results: 1-16 |
Results: 16
Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban
Authors: Marciniak, SJ Jordan, RE Mascelli, MA
Citation: Sj. Marciniak et al., Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban, THROMB HAEM, 85(3), 2001, pp. 539-543
In vitro dose response to different GPIIb/IIIa-antagonists: Inter-laboratory comparison of various platelet function tests
Authors: Harder, S Klinkhardt, U Graff, J Westrup, D Kirchmaier, CM Glusa, E Mascelli, MA Marciniak, SJ Just, A Losche, W Breddin, HK
Citation: S. Harder et al., In vitro dose response to different GPIIb/IIIa-antagonists: Inter-laboratory comparison of various platelet function tests, THROMB RES, 102(1), 2001, pp. 39-48
Abciximab readministration - Results of the ReoPro readministration registry
Authors: Tcheng, JE Kereiakes, DJ Lincoff, AM George, BS Kleiman, NS Sane, DC Cines, DB Jordan, RE Mascelli, MA Langrall, MA Damaraju, L Schantz, A Effron, MB Braden, GA
Citation: Je. Tcheng et al., Abciximab readministration - Results of the ReoPro readministration registry, CIRCULATION, 104(8), 2001, pp. 870-875
Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization
Authors: Lincoff, AM Kereiakes, DJ Mascelli, MA Deckelbaum, LI Barnathan, ES Patel, KK Frederick, B Nakada, MT Topol, EJ
Citation: Am. Lincoff et al., Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization, CIRCULATION, 104(2), 2001, pp. 163-167
Platelet glycoprotein IIIa PIA polymorphism and effects of aspirin on thrombin generation - Response
Authors: Bray, PF Goldschmidt-Clermont, P Furman, MI Michelson, AD Barnard, MR Mascelli, MA Hendrix, C Coleman, L Hamlington, J Kickler, T Christie, DJ Kundu, S
Citation: Pf. Bray et al., Platelet glycoprotein IIIa PIA polymorphism and effects of aspirin on thrombin generation - Response, CIRCULATION, 103(6), 2001, pp. E33-E34
Ticlopidine enhances the platelet inhibitory capacity of abciximab in vitro
Authors: Kleiman, NS Graziadei, N Jordan, RE Lance, ET Fischer, A Maresh, K Edwards, A Mascelli, MA
Citation: Ns. Kleiman et al., Ticlopidine enhances the platelet inhibitory capacity of abciximab in vitro, J THROMB TH, 9(1), 2000, pp. 29-36
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy
Authors: Sane, DC Damaraju, LV Topol, EJ Cabot, CF Mascelli, MA Harrington, RA Simoons, ML Califf, RM
Citation: Dc. Sane et al., Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy, J AM COL C, 36(1), 2000, pp. 75-83
GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood
Authors: Furman, MI Krueger, LA Frelinger, AL Barnard, MR Mascelli, MA Nakada, MT Michelson, AD
Citation: Mi. Furman et al., GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood, THROMB HAEM, 84(3), 2000, pp. 492-498
Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists
Authors: Michelson, AD Furman, MI Goldschmidt-Clermont, P Mascelli, MA Hendrix, C Coleman, L Hamlington, J Barnard, MR Kickler, T Christie, DJ Kundu, S Bray, PF
Citation: Ad. Michelson et al., Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists, CIRCULATION, 101(9), 2000, pp. 1013-1018
High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction - Results from TIMI (thrombolysis in myocardial infarction) 14
Authors: Coulter, SA Cannon, CP Ault, KA Antman, EM Van de Werf, F Adgey, AJJ Gibson, CM Giugliano, RP Mascelli, MA Scherer, J Barnathan, ES Braunwald, E Kleiman, NS
Citation: Sa. Coulter et al., High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction - Results from TIMI (thrombolysis in myocardial infarction) 14, CIRCULATION, 101(23), 2000, pp. 2690-2695
Effects of abciximab, ticlopidine, and combined abciximab/ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty
Authors: Fredrickson, BJ Turner, NA Kleiman, NS Graziadei, N Maresh, K Mascelli, MA Effron, MB McIntire, LV
Citation: Bj. Fredrickson et al., Effects of abciximab, ticlopidine, and combined abciximab/ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty, CIRCULATION, 101(10), 2000, pp. 1122-1129
Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: Ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions
Authors: Kleiman, NS Grazeiadei, N Maresh, K Taylor, RJ Frederick, B Lance, ET Effron, MB Jordan, RE Mascelli, MA
Citation: Ns. Kleiman et al., Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: Ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions, AM HEART J, 140(3), 2000, pp. 492-501
Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonistabciximab
Authors: Mascelli, MA Kleiman, NS Marciniak, SJ Damaraju, L Weisman, HF Jordan, RE
Citation: Ma. Mascelli et al., Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonistabciximab, AM HEART J, 139(4), 2000, pp. 696-703
Pharmacological differentiation of GP IIb/IIIa inhibitors
Authors: Jordan, R Mascelli, MA
Citation: R. Jordan et Ma. Mascelli, Pharmacological differentiation of GP IIb/IIIa inhibitors, EUR H J SUP, 1(E), 1999, pp. E3-E10
Platelet glycoprotein IIb/IIIa antagonists in ischemic cerebrovascular disease
Authors: Leclerc, JR Mascelli, MA Weisman, HF
Citation: Jr. Leclerc et al., Platelet glycoprotein IIb/IIIa antagonists in ischemic cerebrovascular disease, CORON ART D, 10(8), 1999, pp. 575-579
Readministration of abciximab: Interim report of the ReoPro Readministration Registry
Authors: Tcheng, JE Kereiakes, DJ Braden, GA Jordan, RE Mascelli, MA Langrall, MA Effron, MB
Citation: Je. Tcheng et al., Readministration of abciximab: Interim report of the ReoPro Readministration Registry, AM HEART J, 138(1), 1999, pp. S33-S38
Risultati: 1-16 |